Cite
Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial.
MLA
Auer, Rebecca C., et al. “Efficacy and Safety of Extended Duration to Perioperative Thromboprophylaxis with Low Molecular Weight Heparin on Disease-Free Survival after Surgical Resection of Colorectal Cancer (PERIOP-01): Multicentre, Open Label, Randomised Controlled Trial.” BMJ: British Medical Journal, vol. 378, no. 8352, Sept. 2022, pp. 1–8. EBSCOhost, https://doi.org/10.1136/bmj-2022-071375.
APA
Auer, R. C., Ott, M., Karanicolas, P., Brackstone, M. R., Ashamalla, S., Weaver, J., Tagalakis, V., Boutros, M., Stotland, P., Caycedo Marulanda, A., Moloo, H., Jayaraman, S., Patel, S., Le Gal, G., Spadafora, S., MacLellan, S., Trottier, D., Jonker, D., Asmis, T., & Mallick, R. (2022). Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial. BMJ: British Medical Journal, 378(8352), 1–8. https://doi.org/10.1136/bmj-2022-071375
Chicago
Auer, Rebecca C., Michael Ott, Paul Karanicolas, Muriel Rebecca Brackstone, Shady Ashamalla, Joel Weaver, Vicky Tagalakis, et al. 2022. “Efficacy and Safety of Extended Duration to Perioperative Thromboprophylaxis with Low Molecular Weight Heparin on Disease-Free Survival after Surgical Resection of Colorectal Cancer (PERIOP-01): Multicentre, Open Label, Randomised Controlled Trial.” BMJ: British Medical Journal 378 (8352): 1–8. doi:10.1136/bmj-2022-071375.